High-Dose Probiotics for the Treatment of Active Pouchitis

Purpose

Pouchitis is the major long-term complication after ileal-pouch anal anastomosis for ulcerative colitis. Broad-spectrum antibiotics are the mainstay of treatment in this condition. Recently, we have shown the efficacy of a highly concentrated probiotic preparation (VSL#3, 900 billions/sachet lyophilized viable bacteria) in preventing relapses of chronic pouchitis and in preventing pouchitis onset. This study was designed to evaluate the efficacy of high-dose VSL#3 in the treatment of mildly active pouchitis.

Methods

Twenty-three consecutive patients with mild pouchitis, defined as a score of between 7 and 12 in the Pouchitis Disease Activity Index, which includes clinical, endoscopic, and histological criteria, were treated with VSL#3, 2 sachets b.i.d. (3600 billion bacteria/day) for four weeks. Symptomatic, endoscopic, and histologic evaluations were undertaken before and after treatment according to Pouchitis Disease Activity Index. Remission was defined as a combination of a Pouchitis Disease Activity Index clinical score of ≤2, endoscopic score of ≤1, and total Pouchitis Disease Activity Index score of ≤4. Patients in remission after treatment were treated with VSL#3, 1 sachet b.i.d. (1800 billion bacteria), as maintenance treatment for six months. The quality of life was assessed with the Inflammatory Bowel Disease Questionnaire.

Results

Sixteen of 23 patients (69 percent) were in remission after treatment. The median total Pouchitis Disease Activity Index scores before and after therapy were 10 (range, 9–12) and 4 (range, 2–11), respectively (P < 0.01). The median Inflammatory Bowel Disease Questionnaire score also significantly improved from 110 (range, 90–140) to 200 (range, 95–220; P < 0.001). All 16 patients who went into remission maintained remission during maintenance treatment. Only one patient experienced a transient bloating at the beginning of treatment.

Conclusions

High doses of the probiotic VSL#3 are effective in the treatment of mild pouchitis. Further controlled studies are warranted.

This is a preview of subscription content, log in to check access.

Figure 1
Figure 2

References

  1. 1.

    Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856–60.

    PubMed  CAS  Google Scholar 

  2. 2.

    Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Koch continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993;28:695–700.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234–9.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Löfberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012–8.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Meagher AP, Farouk R, Dozois R, Kelly KA, Pemberton JH. J-ileal pouch-anal anastomosis for CUC: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800–3.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Fazio VW, O'Riordain MG, Lavery IC, et al. Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg 1999;230:575–84.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000;24:851–6.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Sandborn WJ. Pouchitis: definition, risk factors, frequency, natural history, classification, and public perspectives. In: McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN, eds. Trends in inflammatory bowel disease 1996. Lancaster, England: Kluwer Academic Publishers, 1997:51–63.

    Google Scholar 

  9. 9.

    Madden M, McIntyre A, Nicholls RJ. Double-blind cross-over trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193–6.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713–8.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301–5.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Sheperd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy. J Clin Pathol 1987;40:601–7.

    Article  Google Scholar 

  13. 13.

    Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994;69:409–15.

    PubMed  CAS  Google Scholar 

  14. 14.

    Schaafsma G. State of the art concerning probiotic strains in milk products. IDF Nutr Newsl 1996;5:234.

    Google Scholar 

  15. 15.

    Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999;116:1246–9.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Shanahan F. Probiotics in inflammatory bowel diseases. Gut 2001;48:609.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Fabia R, Ar’Rajab A, Johansson M-L, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993;28:155–62.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334–44.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin-10 gene-deficent mice. Gastroenterology 1999;116:1107–14.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299Vs in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002;8:71–80.

    PubMed  Article  Google Scholar 

  21. 21.

    O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219–25.

    Article  CAS  Google Scholar 

  22. 22.

    McCarthy J, O'Mahony L, O'Callaghan L, et al. Double-blind, placebo-controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975–80.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Kruis W, Schuts E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and Mesalazina in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–8.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Rembacken BJ, Snelling AM, Hawkey PM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354:635–9.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with Escherichia Coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–23.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–9.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108–14.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Gionchetti P, Rizzello F, Helvig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003;124:1202–9.

    PubMed  Article  Google Scholar 

  29. 29.

    Venturi A, Gionchetti P, Rizzello F, et al. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5-ASA). Aliment Pharmacol Ther 1999;13:1103–8.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539–46.

    PubMed  Article  Google Scholar 

  31. 31.

    Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–10.

    PubMed  CAS  Google Scholar 

  32. 32.

    Summanen P, Baron EJ, eds. Wadswort anaerobic bacteriology manual. 5th ed. Singapore: STAR Publishers Co., 1993.

    Google Scholar 

  33. 33.

    Hartemink R, Domenech VR, Rombouts FM. LAMVAB-A new selective medium for the isolation of lactobacilli from feces. J Microb Meth 1997;29:77–84.

    Article  CAS  Google Scholar 

  34. 34.

    Hartemink R, Kok BJ, Weenk GH, Rombouts FM. Raffinose-Bifidobacterium (RB) agar, a new selective medium for bifidobacteria. J Microb Meth 1996;27:33–43.

    Article  CAS  Google Scholar 

  35. 35.

    Dave RI, Shah NP. Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and bifidobacteria. J Dairy Sci 1996;76:1529–36.

    Article  Google Scholar 

  36. 36.

    Timisjärvi AT, Alatossava T. Development of oligonucleotide primers from the 16S23S rRNA intergenic sequences for identifying different dairy and probiotic lactic acid bacteria by PCR. Int J Food Microbiol 1997;35:49–56.

    Article  Google Scholar 

  37. 37.

    Kok RG, De Wall A, Schut F, Welling GW, Weenk G, Hellingwerf KJ. Specific detection and analysis of a probiotic Bifidobacterium strain in infant faeces. Appl Environ Microbiol 1996;62:3668–72.

    PubMed  CAS  Google Scholar 

  38. 38.

    Brigidi P, Vitali B, Swennen E, Altomare L, Rossi M, Matteuzzi D. Specific detection of Bifidobacterium strains in a new probiotic preparation and in human feces by polymerase chain reaction. Syst Appl Microbiol 2000;23:391–9.

    PubMed  CAS  Google Scholar 

  39. 39.

    Ruseler-van-Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 114;35:658–64.

  40. 40.

    Ulisse S, Gionchetti P, D'Alò S, et al. Expression of cytokines, inducible nitric oxide synthetase and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001;96:2691–9.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004;53:1602–9.

    PubMed  Article  CAS  Google Scholar 

References

  1. 1.

    Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg 1995;222:120–7.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Pardi DS, Sandborn WJ. Management of pouchitis. Aliment Pharmacol Ther 2006;23:1087–96.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Shepherd NA, Hulten L, Tytgat GN, et al. Workshop: Pouchitis. Int J Colorectal Dis 1989;4:205–29.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000;24:851–6.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Lim M, Sagar P, Finan P, et al. Dybiosis and pouchitis. Br J Surg 2006;93:1325–34.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Duffy M, O'Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002;45:384–8.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Gosselink MP, Schouten WR, van Lieshout LM, et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004;47:1519–25.

    PubMed  Article  Google Scholar 

  8. 8.

    Santavirta J, Mattila J, Kokki M, Matikainen M. Mucosal morphology and fecal bacteriology after ileoanal anastomosis. Int J Colorect Dis 1991;6:38–41.

    Article  CAS  Google Scholar 

  9. 9.

    Smith FM, Coffey JC, Kell MR, et al. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis 2005;7:563–70.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Nasmyth DG, Godwin PG, Dixon MF, et al. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology 1989;96:817–24.

    PubMed  CAS  Google Scholar 

  11. 11.

    Nicholls RJ, Belliveau P, Neill M, et al. Restorative proctocolectomy with ileal reservoir: a pathopysiological assessment. Gut 1981;22:462–8.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Ruseler-van Embden JG, Schouten WR, van Leieshout LM. Pouchitis: result of microbial imbalance? Gut 1994;35:658–64.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Brandi G. Chaussade S, Ladire M, et al. Analysis of ileal bacterial flora in patients with ileal-anal anastomosis with and without pouchitis. Gut 1992;33(Suppl 2):S41.

    Google Scholar 

  14. 14.

    Ohge H, Furne JK, Springfield J, et al. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005;48:469–75.

    PubMed  Article  Google Scholar 

  15. 15.

    Iwaya A, Iiai T, Okamoto H, et al. Change in the bacterial flora of pouchitis. Hepatogastroenterology 2006;53:55–9.

    PubMed  Google Scholar 

  16. 16.

    Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55:833–41.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Onderdonk AB, Dvorak AM, Cisneros RL, et al. Microbial assessment of tissue biopsy samples from ileal pouch patients. J Clin Microbiol 1992;30:312–7.

    PubMed  CAS  Google Scholar 

  18. 18.

    O'Connell PR, Rankin DR, Weiland LH, Kelly KA. Enteric bacteriology, absorption, morphology and emptying after ileal pouch-anal anastomosis. Br J Surg 1986;73:909–14.

    Article  CAS  Google Scholar 

  19. 19.

    Kmiot WA, Youngs D, Tudor R, et al. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg 1993;80:1445–9.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713–8.

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497–500.

    PubMed  CAS  Google Scholar 

  22. 22.

    Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16909–17.

  23. 23.

    Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193–6.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301–5.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002;16:27–34.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–9.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108–14.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202–9.

    PubMed  Article  Google Scholar 

  29. 29.

    Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel disease. Drugs 2006;66:1371–87.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721–8.

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Gosselink M, Schouten WR, van Lieshout LM, et al. Delay of first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47:876–84.

    PubMed  Article  Google Scholar 

  32. 32.

    Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003;17:509–15.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Paolo Gionchetti M.D..

Additional information

Dr. Pardi does consulting and research for Salix.

About this article

Cite this article

Gionchetti, P., Rizzello, F., Morselli, C. et al. High-Dose Probiotics for the Treatment of Active Pouchitis. Dis Colon Rectum 50, 2075–2084 (2007). https://doi.org/10.1007/s10350-007-9068-4

Download citation

Key words

  • Ulcerative colitis
  • Pouchitis
  • Probiotics